A new curcumin analogue with potent suppressive activity in pancreatic cancer

一种新的姜黄素类似物,对胰腺癌具有有效的抑制活性

基本信息

  • 批准号:
    7874486
  • 负责人:
  • 金额:
    $ 7.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-08-01 至 2012-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Several oncogenic pathways are typical overexpressed and activated in pancreatic cancer, which include AKT, Signal Transducer and Activator of Transcription 3 (STAT3), Notch-1, and NF-?B. An effective therapeutic agent may need to exhibit the capacity to inhibit these pathways. STAT3, Notch-1, NF-?B, and AKT pathways are among the major oncogenic pathways activated in pancreatic cancer. These four oncogenic pathways are considered to play critical roles in growth, survival, invasion, angiogenesis, and other functions in pancreatic cancer and thereby emerged as attractive therapeutic targets for this cancer. We proposed to evaluate the inhibitory efficacy of GO-Y030, a new and more potent analogue of the dietary agent, curcumin. Our preliminary results in this proposal demonstrated for the first time that GO-Y030 is approximately 26-397 times more potent than curcumin in inhibiting pancreatic cancer cell viability as well as more potent than cu cell lines. We will also examine whether the expression of STAT3, AKT, and Notch-1 can rescue the inhibitory effects of GO-Y030 in pancreatic cancer cells. In specific aim 2, we will evaluate the inhibitory efficacy of GO-Y030 to suppress PANC-1, MIA-PACA-2, and BxPC-3 pancreatic cancer cells in orthotopic tumor model. Pancreatic cancer is one of the most serious types of cancer and there is a critical need to develop more effective therapeutic agents for pancreatic cancer. Our proposed studies, if successful, will provide a promising potential using GO-Y030 as a novel therapeutic agent for pancreatic cancer with the ultimate goal to reduce the mortality of pancreatic cancer and extending the quality of healthy life for people in this country and around the world. PUBLIC HEALTH RELEVANCE: Each year about 32,000 individuals in the United States are diagnosed with pancreatic cancer. Cancer of the exocrine pancreas is rarely curable and has an overall survival rate of less than 4%. The. itical need for better treatment approaches for pancreatic cancer. The objectives of this proposal are to evaluate the inhibitory efficacy of a new and highly potent curcumin analogue, GO-Y030 in human pancreatic cancer cells in vitro and in a mouse orthotopic tumor model. These results will provide the pre- clinical activities of GO-Y030 as a potential therapeutic agent for more effective treatment for pancreatic cancer
描述(由申请人提供):胰腺癌中几种致癌途径典型地过表达和激活,包括AKT、信号转导和转录激活因子3(STAT 3)、Notch-1和NF-?B。有效的治疗剂可能需要表现出抑制这些途径的能力。STAT3、Notch-1、NF-?B和AKT途径是胰腺癌中激活的主要致癌途径之一。这四种致癌途径被认为在胰腺癌的生长、存活、侵袭、血管生成和其他功能中起关键作用,从而成为这种癌症的有吸引力的治疗靶点。我们建议评估GO-Y 030的抑制功效,GO-Y 030是一种新的更有效的膳食剂姜黄素类似物。我们在该提案中的初步结果首次证明,GO-Y 030在抑制胰腺癌细胞活力方面比姜黄素强约26-397倍,并且比cu细胞系更有效。我们还将研究STAT 3,AKT和Notch-1的表达是否可以挽救GO-Y 030在胰腺癌细胞中的抑制作用。在具体目标2中,我们将评估GO-Y 030在原位肿瘤模型中抑制PANC-1、MIA-PACA-2和BxPC-3胰腺癌细胞的抑制功效。胰腺癌是最严重的癌症类型之一,迫切需要开发更有效的胰腺癌治疗药物。我们提出的研究,如果成功,将提供一个有前途的潜力,使用GO-Y 030作为胰腺癌的新型治疗药物,最终目标是降低胰腺癌的死亡率,并延长健康生活的质量,为人们在这个国家和世界各地。公共卫生相关性:美国每年约有32,000人被诊断患有胰腺癌。胰腺外分泌部的癌症很少能治愈,总生存率低于4%。的. 胰腺癌治疗方法的改进本提案的目的是评估一种新的高效姜黄素类似物GO-Y 030在体外人胰腺癌细胞和小鼠原位肿瘤模型中的抑制功效。这些结果将提供GO-Y 030作为胰腺癌更有效治疗的潜在治疗剂的临床前活性

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Targeting colon cancer stem cells using a new curcumin analogue, GO-Y030.
使用新型姜黄素类似物 GO-Y030 靶向结肠癌干细胞
  • DOI:
    10.1038/bjc.2011.200
  • 发表时间:
    2011-07-12
  • 期刊:
  • 影响因子:
    8.8
  • 作者:
    Lin, L.;Liu, Y.;Li, H.;Li, P-K;Fuchs, J.;Shibata, H.;Iwabuchi, Y.;Lin, J.
  • 通讯作者:
    Lin, J.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jiayuh Lin其他文献

Jiayuh Lin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jiayuh Lin', 18)}}的其他基金

Co-Targeting IL-6 and CDK4/6 Pathways as a Novel Approach of Preventive Therapy for Triple-Negative Breast Cancer
共同靶向 IL-6 和 CDK4/6 通路作为三阴性乳腺癌预防性治疗的新方法
  • 批准号:
    10365726
  • 财政年份:
    2022
  • 资助金额:
    $ 7.63万
  • 项目类别:
Co-Targeting IL-6 and CDK4/6 Pathways as a Novel Approach of Preventive Therapy for Triple-Negative Breast Cancer
共同靶向 IL-6 和 CDK4/6 通路作为三阴性乳腺癌预防性治疗的新方法
  • 批准号:
    10655282
  • 财政年份:
    2022
  • 资助金额:
    $ 7.63万
  • 项目类别:
A novel STAT3-selective inhibitor for medulloblastoma therapy
一种用于髓母细胞瘤治疗的新型 STAT3 选择性抑制剂
  • 批准号:
    9291724
  • 财政年份:
    2016
  • 资助金额:
    $ 7.63万
  • 项目类别:
Repositioning Bazedoxifene as a novel IL-6/GP130 inhibitor for sarcoma therapy
将巴多昔芬重新定位为用于肉瘤治疗的新型 IL-6/GP130 抑制剂
  • 批准号:
    9291661
  • 财政年份:
    2016
  • 资助金额:
    $ 7.63万
  • 项目类别:
Repositioning Bazedoxifene as a novel IL-6/GP130 inhibitor for sarcoma therapy
将巴多昔芬重新定位为用于肉瘤治疗的新型 IL-6/GP130 抑制剂
  • 批准号:
    8996140
  • 财政年份:
    2015
  • 资助金额:
    $ 7.63万
  • 项目类别:
THE ROLE OF STAT3 SIGNALING IN CHILDHOOD SARCOMAS
STAT3 信号传导在儿童肉瘤中的作用
  • 批准号:
    8516641
  • 财政年份:
    2013
  • 资助金额:
    $ 7.63万
  • 项目类别:
A new curcumin analogue with potent suppressive activity in pancreatic cancer
一种新的姜黄素类似物,对胰腺癌具有有效的抑制活性
  • 批准号:
    7740282
  • 财政年份:
    2009
  • 资助金额:
    $ 7.63万
  • 项目类别:
Evaluation of a novel AKT inhibitor in ovarian cancer
新型 AKT 抑制剂治疗卵巢癌的评价
  • 批准号:
    6703347
  • 财政年份:
    2004
  • 资助金额:
    $ 7.63万
  • 项目类别:
Evaluation of a novel AKT inhibitor in ovarian cancer
新型 AKT 抑制剂治疗卵巢癌的评价
  • 批准号:
    7017651
  • 财政年份:
    2004
  • 资助金额:
    $ 7.63万
  • 项目类别:
Regulation of Stat3 by p53 in cancer Cells
癌细胞中 p53 对 Stat3 的调节
  • 批准号:
    6779707
  • 财政年份:
    2002
  • 资助金额:
    $ 7.63万
  • 项目类别:

相似海外基金

Nutrient bioavailability and metal toxicity with a focus on the influence of geochemical parameters on the biological availability of trace metals
营养物生物利用度和金属毒性,重点关注地球化学参数对微量金属生物利用度的影响
  • 批准号:
    346752-2007
  • 财政年份:
    2007
  • 资助金额:
    $ 7.63万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Master's
SGER: Development of a Reporter System Regulated by the Biological Availability of Fe in Saltwater
SGER:开发由盐水中铁的生物有效性调节的报告系统
  • 批准号:
    0002968
  • 财政年份:
    2000
  • 资助金额:
    $ 7.63万
  • 项目类别:
    Standard Grant
Pollutants in sediments and their environmental impact, esp speciation and biological availability of metals
沉积物中的污染物及其环境影响,特别是金属的形态和生物有效性
  • 批准号:
    5555510-1995
  • 财政年份:
    1995
  • 资助金额:
    $ 7.63万
  • 项目类别:
    Bilateral Exchange Program (H)
Iron Speciation and Its Biological Availability in Seawater: A Workshop
海水中铁形态及其生物有效性:研讨会
  • 批准号:
    9314179
  • 财政年份:
    1994
  • 资助金额:
    $ 7.63万
  • 项目类别:
    Standard Grant
Biological availability of amino acids from Canadian fish meals and fish silage in Atlantic salmo diets
大西洋鲑日粮中加拿大鱼粉和鱼青贮饲料中氨基酸的生物利用度
  • 批准号:
    45874-1989
  • 财政年份:
    1991
  • 资助金额:
    $ 7.63万
  • 项目类别:
    Collaborative Research and Development Grants - Government (H)
Marine Humic Substances: Formation Via Vascular Plant Degradation and Biological Availability
海洋腐殖质:通过维管植物降解和生物利用度形成
  • 批准号:
    9116450
  • 财政年份:
    1991
  • 资助金额:
    $ 7.63万
  • 项目类别:
    Continuing Grant
Special Foreign Currency Award (Including 3,900 Egyptian POunds) For Study of Some Factors Affecting Biological Availability of Drugs
影响药物生物利用度的部分因素研究特别外币奖(含3,900埃及镑)
  • 批准号:
    7310592
  • 财政年份:
    1973
  • 资助金额:
    $ 7.63万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了